Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

China beckons to clinical trial sponsor

Article Abstract:

The Danish Center for Clinical and Basic Research (CCBR) announced its intention to establish clinical research facilities in Beijing, independent of the state authorities, indicating that the clinical trials market is opening up in China. The main incentives for clinical trail outsourcing to China are low cost, ease of access to patients, better medication, and transportation infrastructures.

Author: Hepeng Jia
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Denmark, Foreign operations, Research & Development, Scientific Research and Development Services, Research & Development NEC, Research institutes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


China kickstart its vaccine market

Article Abstract:

China introduces a major commercialization policy that includes a budget to support research in the country's vaccine industry. The biotech section chief at the National Development and Reform Commission stated that this policy is to take vaccine as a breakthrough point to promote the innovation of the whole biotech sector.

Author: Hepeng Jia
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Legal issues & crime, Government regulation (cont), Government expenditures, Government domestic functions, Government regulation, Science & research, Drugs, Legal/Government Regulation, Research, Laws, regulations and rules, Biological products industry, Science and technology policy, Government finance

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Chinese manufacturers vie for piece of outsourcing pie

Article Abstract:

Chinese drug companies are aiming for more outsourcing deals because of its traditional advantages of a low cost base and major inward investment, supported by increasingly innovative R&D and improving standards of good manufacturing practice (GMP).

Author: Hepeng Jia
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Management dynamics, Pharmaceutical preparations, Management, Pharmaceutical industry, Company business management

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: China, Outsourcing
Similar abstracts:
  • Abstracts: China offers alternative gateways for experimental drugs. China moves to reform biotech policies. China ramps up efforts to commercialize GM rice
  • Abstracts: MyChelle Lip Products. Chanel Le Crayon Gloss Sheer Lip Colouring Pencil. Lancome Platineum Anti-Aging Moiturizer
  • Abstracts: Mrs Dash Salt-Free All Natural Seasoning Blend. French's Skillet Starters Seasoning Mixes
  • Abstracts: Big biotech embraces direct-to-consumer advertising . Biotech jostles with pharma for slice of HIV market. Teva to acquire Chinese biogenerics manufacturer
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.